NCT01338831View on ClinicalTrials.gov

Phase I Study of LFA102 in Patients With Prolactin Receptor-positive Castration-resistant Prostate Cancer or Prolactin Receptor-positive Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Castration-resistant Prostate CancerMetastatic Breast CancerUterine Leiomyoma
Interventions
DRUG

LFA102

Trial Locations (9)

1000

Novartis Investigative Site, Brussels

1200

Novartis Investigative Site, Brussels

19107

Thomas Jefferson University, Dept. of Phsyciatry & Neurology Thomas Jefferson, Philadelphia

41100

Novartis Investigative Site, Modena

53792

University of Wisconsin Clinical Science Center, Madison

84103

University of Utah / Huntsman Cancer Institute Huntsman 3, Salt Lake City

02114

Massachusetts General Hospital Mass Gen 3, Boston

08901

Cancer Institute of New Jersey SC, New Brunswick

08035

Novartis Investigative Site, Barcelona

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY